During the past few weeks there have been a number of developments in Ovarian Cancer treatment and research in the news. Below are my top three picks.
Bevacizumab (Avastin) for Recurrent Ovarian Cancer
The FDA approved Avastin, a VEGF inhibitor made by Genentech, for treatment of persistent, recurrent or late stage Ovarian Cancer. Avastin can be used with paclitaxel, pegylated liposomal doxorubicin or topotecan chemotherapy.
FDA announce may be found here.
Genentech Press Release and results of the Phase III AURELIA study can be found here.
6th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain News
Researchers identified a biomarker that can predict which
women will respond to rucaparib, a PARP inhibitor. Rucaparib is an oral drug. Dr Elizabeth Swisher said "good responses to rucaparib in women with ovarian cancers exhibiting a
form of cell damage called genomic loss of heterozygosity (LOH), in
which an entire chromosomal region on one copy of the genome is lost" as well as in those who have BRCA1/2 mutations. (http://www.medicalnewstoday.com/releases/285788.php)
Trebananib Fails to Improve Overall Survival
The trial, TRINOVA-1, tested Amgen 's drug, trebananib along with Placitaxel. Results show that there was not a significant improvement in overall survival trebananib was used.
Reuter's article - http://www.reuters.com/article/2014/11/04/us-amgen-study-idUSKBN0IO1EW20141104?feedType=RSSfeedName=healthNews
Dee
Every Day is a Blessing !
1 comment:
Thanks for posting this...I am really excited, as I am brca 2, fallopian tube cancer recurring twice, having carbo weekly and Mg ca125 is now 13. I will likely cut back to every other week and see what my number does. I am hoping if/when I recur, the parp inhibitor can be an option
Post a Comment